ライフサイエンスコーパス: Genentech

1 optosis-inducing monoclonal antibody Apomab (Genentech).

2 rug supply provided by Hoffmann-La Roche and Genentech.

3 ower than bevacizumab acquired directly from Genentech.

4 ute of Neurological Disorders and Stroke and Genentech.

5 National Cancer Institute and Genentech.

6 ion, GHR Foundation, and F Hoffmann-La Roche/Genentech.

7 nal Institutes of Health, the UK Biobank and Genentech.

8 the National Institutes of Health, and Roche Genentech.

9 D Anderson Cancer Center, MDS/AML Moon Shot, Genentech.

10 ared with bevacizumab acquired directly from Genentech (25 mg/mL; P < .05).

11 F Hoffmann-La Roche and Genentech, a member of the Roche group.

12 At Genentech, a method employing PNGase F digestion, fluore

13 D Anderson Cancer Center, MDS/AML Moon Shot, Genentech/AbbVie, and Astex Pharmaceuticals.

14 omized clinical trials from Biogen and Roche/Genentech: ADVANCE, ASCEND, DECIDE, OPERA I & II, and OR

15 VEGF antibody ranibizumab (Lucentis(R)) from Genentech and aflibercept (Eylea(R)) from Regeneron Phar

16 Primary Funding Source: Genentech and Novartis Pharmaceuticals.

17 F Hoffmann-La Roche-Genentech and the Breast Cancer Research Foundation.

18 Genentech and the National Cancer Institute.

19 of Venetoclax (ABT-199, GDC-0199-AbbVie and Genentech) and a drug candidate S55746 (Servier) to the

20 titute of Neurological Disorders and Stroke, Genentech, and Codman.

21 Abbott Laboratories, Genentech, and National Cancer Institute, National Insti

22 e, Amgen, AstraZeneca, Bristol Myers Squibb, Genentech, and Pfizer through the Foundation for the Nat

23 Vemurafenib (Zelboraf; Genentech, CA) is a highly effective oral chemotherapy a

24 vascular endothelial growth factor antibody [Genentech, CA]) in the treatment of colorectal and other

25 of Drug Sensitivity in Cancer (GDSC) and the Genentech Cell Line Screening Initiative (gCSI); (ii) im

26 ery in vitro data and validated it across 18 Genentech compounds without compound-specific fitting.

27 ody weight anti-CD20 (rituximab; a gift from Genentech) every 21 days, starting from day -7 postinfec

28 Future Fund (for conduct in Australia); and Genentech (for conduct in the USA).

29 independent research organizations Roche and Genentech from 2009 to 2020 is described.

30 Safra Foundation, Eli Lilly, GE Healthcare, Genentech, GlaxoSmithKline, Golub Capital, Insitro, Jans

31 o MY), NIAMS (K23AR075872 to LC), and imCORE-Genentech grant 137515 (to Johns Hopkins Medicine on beh

32 A team at Genentech has developed an elegant new technique for com

33 F Hoffmann-La Roche and Genentech Inc, a member of the Roche group.

34 SCLC Working Group, under the sponsorship of Genentech Inc, Roche Pharmaceuticals, and OSI Pharmaceut

35 Bevacizumab (Avastin; Genentech Inc, South San Francisco, CA) 5 mg/kg was admi

36 Bevacizumab (Avastin; Genentech Inc, South San Francisco, CA), a recombinant,

37 F Hoffmann-La Roche Ltd and Genentech Inc.

38 terization of several CE assays developed at Genentech Inc.

39 luorescence (LIF) detection was developed at Genentech Inc. as part of the control system for the qua

40 he relative effects of bevacizumab (Avastin; Genentech, Inc, South San Francisco, CA) and ranibizumab

41 ng the effect of ranibizumab (RBZ; Lucentis; Genentech, Inc, South San Francisco, CA) in patients wit

42 Hoffmann-La Roche Ltd, Genentech, Inc.

43 an Francisco, CA) and ranibizumab (Lucentis; Genentech, Inc.), using findings from a Cochrane Eyes an

44 N-linked glycans on glycoprotein products at Genentech, Inc., is a capillary electrophoresis (CE) bas

45 r 0.5 mg intravitreal ranibizumab (Lucentis; Genentech, Inc., South San Francisco, CA) or sham inject

46 Genentech investigator-initiated trial funding, Clinical

47 Company-sponsored (Genentech or Novartis) studies in DME completed as of De

48 d of cancer cell lines from ENCODE, CCLE and Genentech projects.

49 ct their future application in the Roche and Genentech research groups.

50 Beigene, Genentech (Roche), Grais-Cutler Fund, Lymphoma Research

51 National Institutes of Health, Genentech, Roche Laboratories, Lilly Research Laboratori

52 The strategy articulated here is based on Genentech's internal experience for a program intended f

53 to case studies of Alnylam's RNAi platform, Genentech's therapeutic antibody platform, and Moderna's

54 ed anti-HER2 monoclonal antibody (Herceptin; Genentech, San Francisco, CA), should be considered for

55 esfield, UK) or erlotinib (Tarceva, OSI-774; Genentech, South San Francisco, CA) across a variety of

56 stromal tumors or anti-HER2/neu (Herceptin; Genentech, South San Francisco, CA) for treatment of bre

57 rapy or combined with ranibizumab (Lucentis; Genentech, South San Francisco, CA) in patients with neo

58 The use of trastuzumab (Herceptin; Genentech, South San Francisco, CA) in women with UPSC s

59 Ranibizumab (rhuFab V2; Lucentis, Genentech, South San Francisco, CA) is a humanized monoc

60 Bevacizumab (Avastin; Genentech, South San Francisco, CA) is a recombinant, hu

61 e anti-HER2 monoclonal antibody trastuzumab (Genentech, South San Francisco, CA), particularly in pat

62 The anti-IgE medication omalizumab (Xolair; Genentech, South San Francisco, Calif) might allow more

63 oval of the ranibizumab injection (Lucentis; Genentech, South San Francisco, California, USA) are off

64 d to hereafter by its trade name, Herceptin, Genentech USA), we have developed a versatile approach t

65 e anti-HER2 antibody trastuzumab (Herceptin, Genentech), we synthesized a trastuzumab-SPP-Rhodamine r

66 monoclonal antibody, Trastuzumab (Herceptin; Genentech), with chemotherapy is the current standard of